HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

This study is testing a combination treatment — HAIC (a way to deliver chemotherapy directly to the liver through an artery), camrelizumab (an immunotherapy drug), and rivoceranib (a targeted anti-tumor drug) — for people with a rare form of liver cancer called mixed hepatocellular-cholangiocarcinoma. **You may be eligible if...** - You are 18 or older - You have been diagnosed with mixed hepatocellular-cholangiocarcinoma (a liver cancer that has features of both main liver cancer types), confirmed by biopsy - Your cancer cannot be removed by surgery or treated with local therapies - You have not received prior systemic (whole-body) treatment for liver cancer - Your liver function is acceptable (Child-Pugh score 5–7) and overall health is good **You may NOT be eligible if...** - You have already received systemic cancer treatment for liver cancer - You have uncontrolled hepatitis B (viral load too high) - Your liver or blood function is too compromised - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.